Patents by Inventor Valerjans Kauss
Valerjans Kauss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8692021Abstract: Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane or a pharmaceutically acceptable salt thereof (Neramexane), comprising step (iv): (iv) hydrolyzing a mixture comprising an acid, 1-formamido-1,3,3,5,5-pentamethylcyclohexane and hydrogen cyanide to yield 1-amino-1,3,3,5,5-pentamethylcyclohexane.Type: GrantFiled: September 24, 2010Date of Patent: April 8, 2014Assignee: Merz Pharma GmbH & Co. KGaAInventors: Markus-Rene Gold, Valerjans Kauss, Aigars Jirgensons
-
Patent number: 8288549Abstract: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.Type: GrantFiled: September 30, 2009Date of Patent: October 16, 2012Assignee: Merz Pharma GmbH & Co. KGaAInventors: Markus Henrich, Angela Bauer, Jens Nagel, Meik Sladek, Christopher Graham Raphael Parsons, Wojciech Danysz, Valerjans Kauss, Jevgenijs Rozhkovs, Igors Starchenkovs, Dina Trifanova
-
Publication number: 20120245391Abstract: Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane or a pharmaceutically acceptable salt thereof (Neramexane), comprising step (iv): (iv) hydrolyzing a mixture comprising an acid, 1-formamido-1,3,3,5,5-pentamethylcyclohexane and hydrogen cyanide to yield 1-amino-1,3,3,5,5-pentamethylcyclohexane.Type: ApplicationFiled: September 24, 2010Publication date: September 27, 2012Applicant: MERZ PHARMA GmbH &CO. KGaAInventors: Markus-Rene Gold, Valerjans Kauss, Aigars Jirgensons
-
Publication number: 20120220577Abstract: The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.Type: ApplicationFiled: June 4, 2010Publication date: August 30, 2012Inventors: Markus Henrich, Angela Hansen, Jens Nagel, Valerjans Kauss, Jevgenijs Rozhkovs, Ginta Grunsteine, Dina Trifanova
-
Publication number: 20120178742Abstract: The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: ApplicationFiled: August 3, 2010Publication date: July 12, 2012Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Markus Henrich, Tanja Weil, Mirko Hechenberger, Sibylle Muller, Valerjans Kauss, Ronalds Zemribo, Elina Erdmane, Gints Smits
-
Publication number: 20110212956Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.Type: ApplicationFiled: May 3, 2011Publication date: September 1, 2011Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaitas, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Publication number: 20110190342Abstract: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.Type: ApplicationFiled: September 30, 2009Publication date: August 4, 2011Inventors: Markus Henrich, Angela Bauer, Jens Nagel, Meik Sladek, Christopher Graham Raphael Parsons, Wojciech Danysz, Valerjans Kauss, Jevgenijs Rozhkovs, Igos Starchenkovs, Dina Trifanova
-
Patent number: 7985753Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.Type: GrantFiled: August 3, 2007Date of Patent: July 26, 2011Assignee: MERZ PHARMA GmbH & Co. KGaAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Patent number: 7947689Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.Type: GrantFiled: August 3, 2007Date of Patent: May 24, 2011Assignee: Merz Pharma GmbH & Co. KGaAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Publication number: 20110003820Abstract: The invention relates to pyrazolopyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: ApplicationFiled: January 30, 2009Publication date: January 6, 2011Applicant: MERZ PHARMA GMBH & CO. KGaAInventors: Markus Henrich, Tanja Weil, Sibylle Muller, Jens Nagel, Andreas Gravius, Valerjans Kauss, Ronalds Zemribo, Elina Erdmane
-
Publication number: 20100298442Abstract: Certain 1-aminoalkylcyclohexanes are systematically-active 5HT3 and nicotinic receptor antagonists and are useful in the inhibition of progression of or alleviation of conditions resulting from disturbances of serotoninergic or nicotinergic transmission giving them a wide range of utility in the treatment of CNS-disorders. Pharmaceutical compositions thereof for such purpose and method of making same, as well as a method-of-treating conditions which are alleviated by the employment of a 5HT3 or neuronal nicotinic receptor antagonist.Type: ApplicationFiled: July 26, 2010Publication date: November 25, 2010Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Christopher Graham Raphael Parsons, Wojciech Danysz, Markus Gold, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons
-
Patent number: 7598384Abstract: The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: GrantFiled: February 25, 2005Date of Patent: October 6, 2009Assignee: Merz Pharma GmbH & Co. KGAAInventors: Aigars Jirgensons, Christopher Graham Raphael Parsons, Ieva Jaunzeme, Ivars Kalvinsh, Markus Henrich, Maksims Vanejevs, Tanja Weil, Valerjans Kauss, Wojciech Danysz
-
Publication number: 20090227582Abstract: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: ApplicationFiled: May 8, 2009Publication date: September 10, 2009Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Valerjans Kauss, Ieva Jaunzeme, Aigars Jirgensons, Ivars Kalvinsh, Maksims Vanejevs, Markus Henrich, Wojciech Danysz, Claudia Jatzke, Christopher G.R. Parsons, Tanja Weil
-
Patent number: 7550482Abstract: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: GrantFiled: August 24, 2005Date of Patent: June 23, 2009Assignee: Merz Pharma GmbH & Co. KGAAInventors: Valerjans Kauss, Ieva Jaunzeme, Aigars Jirgensons, Ivars Kalvinsh, Maksims Vanejevs, Markus Henrich, Wojciech Danysz, Claudia Jatzke, Christopher Graham Raphael Parsons, Tanja Weil
-
Publication number: 20080039476Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.Type: ApplicationFiled: August 3, 2007Publication date: February 14, 2008Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Publication number: 20080039458Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.Type: ApplicationFiled: August 3, 2007Publication date: February 14, 2008Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Publication number: 20080032998Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 independently represent e.g. hydrogen or C1-6-alkyl; R8 represents a radical R9 or a radical R10, whereby one of the two radicals R8 represents R9 and the other radical R8 represents Ret; R9 represents e.g. a phenyl or thiophene group, and R10 represents e.g. hydrogen or methyl; are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.Type: ApplicationFiled: August 3, 2007Publication date: February 7, 2008Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Publication number: 20070299113Abstract: The invention relates to imidazothiazole derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of various disorders, including acute and/or chronic neurological disorders.Type: ApplicationFiled: June 22, 2007Publication date: December 27, 2007Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Ivars Kalvinsh, Larisa Kaulina, Valerjans Kauss, Ronalds Zemribo, Wojciech Danysz, Markus Henrich, Christopher Graham Raphael Parsons, Tanja Weil, Elina Erdmane
-
Publication number: 20070185151Abstract: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compostions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.Type: ApplicationFiled: April 4, 2007Publication date: August 9, 2007Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Christopher Parsons, Markus Henrich, Wojciech Danysz, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold, Maksims Vanejevs
-
Patent number: 7238703Abstract: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borne virus, anti-HSV and anti-Hepatitis C virus activity.Type: GrantFiled: August 11, 2005Date of Patent: July 3, 2007Assignee: Merz Pharma GmbH & Co. KGAAInventors: Christopher G. R. Parsons, Markus Henrich, Wojciech Danysz, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold, Maksims Vanejevs